Wiskott-Aldrich综合征:577例患者研究确定基因型为疾病严重程度和生存的生物标志物
这项国际回顾性研究纳入来自26个国家的577例WAS变异患者,中位随访8.9年(范围0.3-71.1),共6118患者年。队列15岁和30岁总生存率分别为82%(95%CI 78-87)和70%(95%CI 61-80)。变异类型可预测结局:I类变异(外显子1或2错义变异或内含子热点变异c.559+5G>A)15年OS为93%(89-98)、30年OS为91%(86-97),其他变异(II类)分别为71%(62-81)和48%(34-68),P<.0001。
要点
- I类变异患者15年OS 93%、30年OS 91%,II类变异分别为71%和48%。
- 严重出血(P=.007)、危及生命感染(P<.0001)、自身免疫(P=.004)在I类变异患者中累积发生率显著更晚。
- 恶性肿瘤累积发生率在I类和II类变异间无差异(P=.6)。
核心结论
- 变异类别是预测WAS患者结局的生物标志物。
- 研究证实了WAS疾病严重程度谱并量化了特定疾病相关并发症的风险。
研究设计与样本
- 国际回顾性研究,纳入来自26个国家的577例携带WAS变异的患者。
- 中位随访8.9年(范围0.3-71.1),共6118患者年。
主要发现
- 队列总生存率(在HSCT或GT时删失)15岁时为82%(95%CI 78-87),30岁时为70%(95%CI 61-80)。
- I类变异患者15年OS为93%(89-98),30年OS为91%(86-97);II类变异患者分别为71%(62-81)和48%(34-68),P<.0001。
- 严重出血累积发生率在I类变异患者中显著更晚(P=.007)。
- 危及生命感染累积发生率在I类变异患者中显著更晚(P<.0001)。
- 自身免疫累积发生率在I类变异患者中显著更晚(P=.004)。
关键数值与推荐
- I类变异定义为外显子1或2错义变异或内含子热点变异c.559+5G>A。
- II类变异定义为任何其他变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Wiskott-Aldrich syndrome (WAS) is a multifaceted monogenic disorder with a broad disease spectrum and variable disease severity and a variety of treatment options including allogeneic hematopoietic stem cell transplantation (HSCT) and gene therapy (GT). No reliable biomarker exists to predict disease course and outcome for individual patients. A total of 577 patients with a WAS variant from 26 countries and a median follow-up of 8.9 years (range, 0.3-71.1), totaling 6118 patient-years, were included in this international retrospective study. Overall survival (OS) of the cohort (censored at HSCT or GT) was 82% (95% confidence interval, 78-87) at age 15 years and 70% (61-80) at 30 years. The type of variant was predictive of outcome: patients with a missense variant in exons 1 or 2 or with the intronic hot spot variant c.559+5G>A (class I variants) had a 15-year OS of 93% (89-98) and a 30-year OS of 91% (86-97), compared with 71% (62-81) and 48% (34-68) in patients with any other variant (class II; P < .0001). The cumulative incidence rates of disease-related complications such as severe bleeding (P = .007), life-threatening infection (P < .0001), and autoimmunity (P = .004) occurred significantly later in patients with a class I variant. The cumulative incidence of malignancy (P = .6) was not different between classes I and II. It confirms the spectrum of disease severity and quantifies the risk for specific disease-related complications. The class of the variant is a biomarker to predict the outcome for patients with WAS.
引用
- Vallée TC, Glasmacher JS, Buchner H, et al. Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival. Blood. 2024. PMID: 38579284. doi:10.1182/blood.2023021411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。